Cara Therapeutics reported $221.45M in Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Acadia Pharmaceuticals ACAD:US $ 724.43M 30.74M
Acelrx Pharmaceuticals ACRX:US $ 79.59M 7.76M
Aerie Pharmaceuticals AERI:US $ 355.53M 7.2M
Arena Pharmaceuticals ARNA:US $ 1084.66M 99.28M
Biodelivery Sciences International BDSI:US $ 250.33M 8.2M
Cara Therapeutics CARA:US $ 221.45M 28.77M
Chugai Pharma 4519:JP Y 1275767M 131140M
Depomed DEPO:US $ 312.02M 13.41M
Endo International Ordinary Shares ENDP:US $ 9206.26M 27.91M
Halozyme Therapeutics HALO:US $ 1025.86M 59.28M
Horizon Pharma HZNP:US $ 8207.42M 360.81M
JAZZ PHA JAZZ:US $ 13212.99M 6456.52M
Neurocrine Biosciences NBIX:US $ 1956.4M 110M
Pacira Pharmaceuticals PCRX:US $ 1325.83M 38.28M
Pain Therapeutics PTIE:US $ 281.3M 2.74M
Redhill Biopharma RDHL:US $ 203.67M 16.45M
Revance Therapeutics RVNC:US $ 640.88M 35.07M
Supernus Pharmaceuticals SUPN:US $ 1573.06M 65.62M
Teva Pharmaceutical Industries TEVA:US $ 49195M 191M
Vanda Pharmaceuticals VNDA:US $ 567.64M 24.45M